| Feb 9, 2026 | QuantX Biosciences | $85.0M Series B | Lilly Asia Ventures, Sanofi Ventures | Hongshan Capital Group (Sequoia Capital China) |
| Jan 12, 2026 | Precede Biosciences | $83.5M Debt / Series B | — | 5AM Ventures, Alexandria Venture Investments, Binney Street Capital, Bristol Myers Squibb, Wouter Meuleman, Labcorp, Mirae Asset Capital, Osage University Partners, Tiger Gene, Matthias Kleinz |
| Dec 4, 2025 | SciNeuro | $53.0M Other Equity | ARCH Venture Partners, Lilly Asia Ventures | — |
| Sep 22, 2025 | Avenzo Therapeutics | $60.0M Series B | OrbiMed, SR ONE | Foresite Capital, Deep Track Capital, Delos Capital, INCE Capital, Longwood Fund, NEW Enterprise Associates, Quan Capital, Sands Capital, Sofinnova Investments, Surveyor Capital, TF Capital |
| Sep 5, 2025 | Ronovo Surgical | $67.0M Series D | Johnson & Johnson Innovation | Granite Asia, INCE Capital |
| May 7, 2025 | PAQ Therapeutics | $39.0M Series B | Yuexing SU, Olga Danilchanka | Johnson & Johnson Innovation, Sherpa Healthcare Partners |
| May 1, 2025 | EnChannel Medical | $83.9M Series B | DragonBall Capital, Lilly Asia Ventures | Lapam Capital |
| Mar 1, 2024 | Alumis | $260.0M Series C | Foresite Capital, Srinivas Akkaraju | ARCH Venture Partners, Atlas Venture, Deerfield Management, F Prime Capital, The Column Group, VenBio Partners, Ally Bridge Group, Ayurmaya, Cormorant Asset Management, HBM Healthcare Investments, Nextech, Omega Funds, Piper Heartland Healthcare Capital, SR ONE |
| Feb 19, 2024 | Targeting One | $13.9M Series B | Lilly Asia Ventures | — |
| Jan 1, 2024 | Comanche Biopharma | $75.0M Series B | NEW Enterprise Associates | 8VC, ARCH Venture Partners, Atlas Venture, Kima Ventures, LUX Capital, Picus Capital, #secretfund, Jean Charles Samuelian, Roxanne Varza, F Prime Capital, GV, Longview Ventures |
| Oct 3, 2023 | Akura Medical | $35.0M Series B | Cormorant Asset Management, Gautam Kainth | AMED Ventures, PA MedTech, Unorthodox Ventures |
| Sep 21, 2023 | LYNK Pharmaceuticals | $44.1M Series C | China Grand Prosperity Investment | NEW Alliance Capital |
| Aug 1, 2023 | ADARx Pharmaceuticals | $200.0M Series C | Ricky SUN, Chen YU | Andreessen Horowitz, Frazier Healthcare Partners, ED Mathers, OrbiMed, SR ONE, Third Rock Ventures, Ascenta Capital, BlackRock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Invus, Redmile Group, T. Rowe Price Associates, Venrock, Vivo Capital |
| Mar 27, 2023 | ArriVent Biopharma | $155.0M Series B | Elena Viboch, James Healy | Aihc Capital, Catalio Capital, HBM Healthcare Investments, Hongshan Capital Group (Sequoia Capital China), Infinitum Asset Management, Octagon Capital, Carl Gordon, Shanghai Healthcare Capital, Sirona Capital, Terra Magnum Capital Partners, Unicorn Capital, ZOO Capital |
| Feb 1, 2023 | Ronovo Surgical | $50.0M Other Equity | Jiang Zhang | GGV Capital, Matrix Partners China, Vivo Capital |
| Jan 1, 2023 | ADARx Pharmaceuticals | $46.0M Series B | Lorence KIM | Andreessen Horowitz, Frazier Healthcare Partners, ED Mathers, OrbiMed, SR ONE, Third Rock Ventures, Sirona Capital |
| Nov 16, 2022 | Lupeng Pharmaceutical | $35.0M Pre-Series B | Temasek | Fontus Capital, Kaitai Capital, BIN LI, TF Capital |
| Sep 4, 2022 | Neukio Biotherapeutics | $50.0M Series A | — | IDG Capital, Sherpa Healthcare Partners, Surplus Capital |
| Jul 1, 2022 | GluBio Therapeutics | $22.0M Series A | Qiming Venture Partners | Kaitai Capital |
| Nov 1, 2021 | Hopstem | $40.0M Series B | — | — |
| Oct 1, 2021 | Structure Therapeutics | $100.0M Series B | Mark Nathan Lampert | Qiming Venture Partners, Casdin Capital, Cormorant Asset Management, Eight Roads Ventures, F Prime Capital, Hongshan Capital Group (Sequoia Capital China), Janus Henderson Investors, Monashee Investment Management, Sage Partners, Schr"dinger, Stork Capital, Surveyor Capital, Chen YU, Terra Magnum Capital Partners, TF Capital, Woodline Partners, WuXi AppTec |
| Oct 1, 2021 | CinCor Pharma | $140.0M Series B | Jason Pitts | ARCH Venture Partners, Keno Gutierrez, Soffinova Partners, Sofinnova Investments, Third Rock Ventures, Westlake Village BioPartners, David Morris, Heather Preston, Adage Capital Management, BVF Partners, CinCor Pharma, CinRx Pharma, Omega Funds, Perceptive Advisors, Rock Springs Capital, RTW Investments, Sixty Degree Capital |
| Sep 1, 2021 | ADARx Pharmaceuticals | $75.0M Series B | OrbiMed, SR ONE | Andreessen Horowitz, Frazier Healthcare Partners, ED Mathers, Sirona Capital |
| Aug 29, 2021 | LYNK Pharmaceuticals | $50.0M Series B | Lilly Asia Ventures | Heda Ventures, Legend Capital, MED Fine Capital, NEW Alliance Capital |
| Aug 17, 2021 | Meditrust | $308.7M Series C | Boyu Capital, Janchor Partners | Aihc Capital, Bank OF China Group Investment, China Everbright, China Renaissance, CICC Capital, Lake Bleu Capital, Marathon Venture Partners, NEW Alliance Capital, Shanghai Biopharmaceutical Fund, Sinovation Ventures |
